Integra LifeSciences Holdings C

Valuation Analysis

About the Company

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, suc

Integra LifeSciences Holdings C Stock at a Glance

Integra LifeSciences Holdings C (IART) is currently trading at $17.77 with a market capitalization of $1.4B. The 52-week range spans from $8.70 to $18.05; the current price is 1.6% below the yearly high. Year-over-year revenue growth stands at +2.4%.

💰 Dividend

Integra LifeSciences Holdings C currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

7 analysts rate Integra LifeSciences Holdings C (IART) on consensus: Hold. The average price target is $17.43, implying -1.92% from the current price. Analyst price targets range from $11.00 to $27.00.

Integra LifeSciences Holdings C: The Investment Case in Detail

Integra LifeSciences Holdings C (IART) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Revenue growth has slowed to just 2.4%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 14.15% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

With a PEG ratio of 0.67, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The share is trading at 97% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to market-like volatility, elevated short interest (14.15%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Integra LifeSciences Holdings C?

Compare top-rated brokers — low fees, trusted providers, fully regulated.